Ann: Kazia licenses Cantrixil to Oasmia, page-57

Cantrixil will now be administered differently to ovarian patients in a new phase 2 trial expected to commence during 2022.

"To meet this unmet medical need and help improve the efficiency of the drug development process, Oasmia has developed and patented the XR-17™ drug delivery platform. XR-17 increases the solubility of intravenously delivered compounds and enables Oasmia to develop innovative formulations of APIs.

By combining XR-17 and an effective active pharmaceutical substance, Oasmia can create innovative and patent-protected drugs that benefit patients".

Kazia's phase 1 trial administered cantrixil by:- "Patients must be willing and able to undergo insertion of a port or catheter for intraperitoneal access";

Oasmia states the in-licensing of cantrixil is part of their pearl acquisition program.
Looking forward to my future pearl necklace from the cantrixil phase 2 trial for ovarian cancer and an additional diamond necklace from any future prostate cancer trial with cantrixil.

Cantrixil (TRX-E-002-1) Cantrixil is a proprietary formulation of the potent and selective third-generation benzopyran, TRX-E-002-1. It targets the entire spectrum of cancer cells, including chemotherapy-resistant tumour-initiating cells (‘cancer stem cells’) that are thought to be responsible for disease relapse.

Regards.